Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors

Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors

Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes unive...

Full description

Bibliographic Details
Main Authors: Kasun Wanigasooriya, Robert Tyler, Joao D. Barros-Silva, Yashashwi Sinha, Tariq Ismail, Andrew D. Beggs
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
radiosensitiser
chemoradiotherapy
PI3K
AKT
mTOR inhibitors
rectal cancer
Online Access:https://www.mdpi.com/2072-6694/12/5/1278

Internet

https://www.mdpi.com/2072-6694/12/5/1278

Similar Items